Register Log In Login with facebook

Multiple Sclerosis patients taking fingolimod who had more than 40 ng of Vitamin D had fewer lesions- May 2018

Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod

Neurological Sciences, pp 1–4 , https://doi.org/10.1007/s10072-018-3440-0
L. Ferre’F. ClarelliG. SferruzzaM. A. RoccaE. MasciaM. RadaelliF. SangalliG. Dalla CostaL. MoiolaM. AboulwafaF. Martinelli BoneschiG. ComiM. FilippiV. MartinelliF. Esposito


This study noticed fewer lesions in patients which happen to have > 40 ng of Vitamin D

Over 50,000 Facebook people were members of forums learning about the Coimbra protocol as 2017

90% of MSers have become disease-free when they added enough vitamin D to get Vitamin D > 150 ng

Vitamin D has treated Multiple Sclerosis and autoimmune diseases for 16 years – Coimbra April 2018

Overview MS and vitamin D

Background: Several studies have shown an association between 25-hydroxyvitamin D (25[OH]D) levels and multiple sclerosis (MS) susceptibility and/or level of disease activity in patients treated with first line drugs.

Aims: To investigate whether baseline 25[OH]D values could influence disease activity also during treatment with the second-line drug fingolimod (FTY).

Patients and methods
We enrolled 176 MS patients who started FTY at the San Raffaele Hospital (OSR) MS center with available 25[OH]D measurement at the time of treatment start. We then prospectively followed them for 2 years with periodic clinical examinations and MRI scans.

We found no linear correlation between baseline 25[OH]D levels and annualized relapse rate (ARR) or time to first relapse.
However, we observed that patients with serum 25[OH]D ≥ 100 nmol/l showed a lower number of Gd+ and combined unique activity (CUA) lesions at baseline compared to patients with the lowest 25[OH]D levels (less than 50 nmol/l, p value < 0.05). Moreover, they showed fewer CUA lesions at 2-year follow-up also when accounting for baseline level of disease activity (p value < 0.05).

In patients treated with FTY, those with the highest baseline 25(OH)D levels had a significantly lower number of active lesions at baseline; the same effect, even if weaker, was observed also at 2-year follow-up when adjusting for baseline disease activity. Given Vitamin D supplementation safety profile, also if a causal effect has not yet been shown, most of MS patients could probably benefit from 25[OH]D levels above those currently considered to be sufficient.


  • 1. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296(23):2832–2838
  • 2. Martinelli V, Dalla Costa G, Colombo B, Dalla Libera D, Rubinacci A, Filippi M, Furlan R, Comi G (2014) Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 20(2):147–155
  • 3. Tuzun1 E, Kucukhuseyin O, Kurtuncu M et al (2015) Reduced serum vitamin D levels in neuromyelitis optica. Neurol Sci 36(9):1701–1702. https://doi.org/10.1007/s10072-015-2229-7
  • 4. Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ (2012) Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 79(3):261–266
  • 5. Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, Kappos L, Pohl C (2014) Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 71(3):306–314
  • 6. Fitzgerald KC, Munger KL, Kochert K et al (2015) Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol 72(12):1458–1465
  • 7. Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, Weiner HL, Glanz B, Chitnis T (2015) Effect of vitamin D on MS activity by disease-modifying therapy class. Neurol Neuroimmunol Neuroinflamm 2(6):e167
  • 8. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302
  • 9. Bliss CI (1958) Periodic regression in biology and climatology. Conn Agric Exp Station 615:3–55
  • 10. Hupperts R (2016) High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a. ECTRIMS congress, London

Created by admin. Last Modification: Sunday May 13, 2018 11:06:06 UTC by admin. (Version 6)
See any problem with this page? Report it (FINALLY WORKS)